XOMA-213

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameXOMA-213
Drug Alias NameX 213LFA102LFA-102XOMA-213X-213
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProlactin receptor antagonists
TargetsProlactin receptor
Therapy Area/IndicationsMetastatic breast cancerProstatic Neoplasms, Castration-ResistantBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[5] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesXoma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerProstatic Neoplasms, Castration-ResistantBreast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A